TEVA - Teva Pharmaceutical ...About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $7.26 | Open | $7.22 |
| Volume | 15.3M | Market Cap | 9.657B |
| Yield | Last Dividend |
| J&J's (JNJ) Opioid Lawsuit Verdi... | 7:15 AM |
| J&J (JNJ) is facing several litigation in multiple states related to abuse of its opioid-based drugs. A ruling is expected on Aug 26 in a trial filed ... | |
| Pharma Stock Roundup: ABBV's Rinvoq ... | 6:40 AM |
| FDA approves AbbVie's (ABBV) upadacitinib to be marketed as Rinvoq. Bayer (BAYRY) is set to divest its Animal Health unit to Elanco for $7.6 billi... | |
| MiMedx Has Changed, But Its Critics Have... | 08/22/19 |
| (Bloomberg Opinion) -- This is the second of two columns about MiMedx and the short-sellers. Read the first here.Most of the time, Eiad Asbahi, the 40... | |
| Jim Cramer Weighs In On Pfizer, Teva And... | 08/22/19 |
| On CNBC's "Mad Money Lightning Round," Jim Cramer said Union Pacific Corporation (NYSE: UNP ) is a teriffic stock. He thinks it's a long-term great s... | |
| BeiGene's NDA for Zanubrutinib Gets ... | 08/22/19 |
| The FDA grants priority review to BeiGene's (BGNE) NDA seeking approval for zanubrutinib as a treatment for mantle cell lymphoma. | |
| Mallinckrodt (MNK) Stock Down 70.8% YTD ... | 08/22/19 |
| Mallinckrodt (MNK) crashes 70.8% in the year so far due to various lawsuits and litigations. | |
| Opioid Epidemic: Will Pharmas Scramble T... | 08/21/19 |
| Endo International and Allergan could avoid going to trial in a landmark case out of Ohio accusing pharmaceutical companies of marketing practices tha... | |
| Endo Up on Settlement of a Few Cases Rel... | 08/21/19 |
| Endo (ENDP) finally has some good news for investors with the settlement of a few cases in Ohio related to opioid medications. | |
| Oklahoma judge to rule on Monday in opio... | 08/21/19 |
| An Oklahoma judge will rule on Monday on whether Johnson & Johnson should be held liable in a lawsuit by the state's attorney general who argues the d... | |
| Teva Launches Generic Version of Mylan&#... | 08/21/19 |
| Teva (TEVA) launches generic version of Mylan's (MYL) popular EpiPen Jr allergy treatment at a price of $300 for a pack of two. | |
| Shares of Teva up 3% on positive migrain... | 08/21/19 |
| Shares of Teva Pharmaceutical Industries rose 3% in premarket trade Wednesday after The Lancet published results from a late-stage study showing that... | |
| Buy rating | 08/09/19 |
| BMO Capital maintains Market Perform rating and lowers Price Target from $11.00 to $9.00 | |
| Sell rating | 07/15/19 |
| Morgan Stanley downgrades from Equal-Weight to Underweight rating and lowers Price Target from $16.00 to $6.00 | |
| Sell rating | 06/11/19 |
| Barclays initiates coverage with Underweight rating and announces Price Target of $8.00 | |
| Strong Buy rating | 06/03/19 |
| Oppenheimer upgrades from Perform to Outperform rating and announces Price Target of $12.00 | |
| Underperform rating | 05/30/19 |
| Bank of America downgrades from Buy to Underperform rating and lowers Price Target from $19.00 to $9.00 | |
| Hold rating | 05/28/19 |
| UBS downgrades from Buy to Neutral rating and lowers Price Target from $22.00 to $12.00 | |
| Buy rating | 05/09/19 |
| Wells Fargo maintains Market Perform rating and lowers Price Target from $18.00 to $17.00 | |
| Buy rating | 04/11/19 |
| Citigroup maintains Buy rating and lowers Price Target from $27.00 to $23.00 | |
| Buy rating | 04/03/19 |
| Wells Fargo maintains Market Perform rating and lowers Price Target from $20.00 to $18.00 | |
| Buy rating | 03/28/19 |
| BMO Capital initiates coverage with Market Perform rating and announces Price Target of $18.00 | |
| Hold rating | 03/20/19 |
| SunTrust Robinson Humphrey initiates coverage with Hold rating and announces Price Target of $17.00 | |
| Buy rating | 03/07/19 |
| and announces Price Target of $22.00 | |
| Hold rating | 03/06/19 |
| Morgan Stanley downgrades from Overweight to Equal-Weight rating and announces Price Target of $17.00 | |
| Date | 2019-08-07 (BMO) | Est. (EPS/Rev.) | $0.57/ 4.25B |
| Actual (EPS/Rev.) | $0.60/ $4.34 B | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Equity and Teens | Equity and Teens | 100.00 % | Follow |
| Trading | Trading | 99.00 % | Follow |
| Swing for the fences | Gino Baldassano | 77.00 % | Follow |
| Arbitrage Trade Analytics | Royce Wells | 72.00 % | Subscribe |
| smashingdon | Paul | 70.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
